Sign In
Buy RMD
$188.63
+2.34 (+1.26%)
At Close: Jun 18, 2026
4 Big Upside Potential Picks From RBC Capital Markets
11:05am, Wednesday, 08'th Jun 2022
Given the recent market moves, investors are looking for direction. Guidance from either the Federal Reserve or analysts may offer some credence, in terms of a sign.
ResMed Announces Participation in the 43rd Annual Goldman Sachs Global Healthcare Conference
09:00am, Tuesday, 07'th Jun 2022
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Goldman Sachs Global Healthc
Analyst Ratings for ResMed
03:22pm, Monday, 06'th Jun 2022 Benzinga
Analysts have provided the following ratings for ResMed (NYSE:RMD) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
3
1
0
0
Last 30D
0
Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022
03:12pm, Monday, 06'th Jun 2022 Benzinga
Upgrades
For Ryder System Inc (NYSE:R), Wolfe Research upgraded the previous rating of Underperform to Peer Perform. Ryder System earned $3.59 in the first quarter, compared to $1.09 in the year-ago q
10 Biggest Price Target Changes For Monday
11:45am, Monday, 06'th Jun 2022 Benzinga
Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.
Piper Sandler reduced JOANN Inc. (NASDAQ: JOAN) price target from $11 to $6. JO
Phibro (PAHC) Up 7.6% Since Last Earnings Report: Can It Continue?
03:31pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference
01:00pm, Wednesday, 25'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Bernstein Strategic Decisio
Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study
08:05pm, Wednesday, 18'th May 2022 GlobeNewswire Inc.
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Sleep apnea sufferers can gain health benefits from PAP (positive airway pressure) treatment in as little as two hours per night, according to a study
ResMed Announces Leadership Change
08:05pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new
ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline
12:34pm, Monday, 02'nd May 2022 Zacks Investment Research
Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.
ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline
09:47am, Monday, 02'nd May 2022
Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.
What 3 Analyst Ratings Have To Say About ResMed
10:23pm, Friday, 29'th Apr 2022 Benzinga
Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's b
ResMed (RMD) Q3 2022 Earnings Call Transcript
02:31am, Friday, 29'th Apr 2022 The Motley Fool
RMD earnings call for the period ending March 31, 2022.
ResMed Inc. (RMD) CEO Mick Farrell on Q3 2022 Results - Earnings Call Transcript
11:15pm, Thursday, 28'th Apr 2022
ResMed Inc. (NYSE:RMD ) Q3 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO Brett Sandercock - CFO Rob Do
ResMed (RMD) Q3 Earnings and Revenues Lag Estimates
09:45pm, Thursday, 28'th Apr 2022 Zacks Investment Research
ResMed (RMD) delivered earnings and revenue surprises of -8.33% and 4.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
